All Outputs (2)

Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma (2018)
Journal Article
Grill, J., Massimino, M., Bouffet, E., Azizi, A. A., McCowage, G., Cañete, A., …Giangaspero, F. (2018). Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma. Journal of Clinical Oncology, 36(10), https://doi.org/10.1200/JCO.2017.76.0611

Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (... Read More about Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma.

Brain Activation in Response to Personalized Behavioral and Physiological Feedback From Self-Monitoring Technology: Pilot Study (2017)
Journal Article
Whelan, M. E., Morgan, P. S., Sherar, L. B., Kingsnorth, A. P., Magistro, D., & Esliger, D. W. (2017). Brain Activation in Response to Personalized Behavioral and Physiological Feedback From Self-Monitoring Technology: Pilot Study. Journal of Medical Internet Research, 19(11), Article e384. https://doi.org/10.2196/jmir.8890

Background: The recent surge in commercially available wearable technology has allowed real-time self-monitoring of behavior (eg, physical activity) and physiology (eg, glucose levels). However, there is limited neuroimaging work (ie, functional mag... Read More about Brain Activation in Response to Personalized Behavioral and Physiological Feedback From Self-Monitoring Technology: Pilot Study.